CVS Health (CVS - Free Report) shares jumped 0.50% during regular trading hours Tuesday in continuation of a strong month for the pharmacy firm. So, let’s see what to expect from CVS’ fourth-quarter financial results that are due out before the opening bell Wednesday.
Overview
CVS completed its nearly $70 billion acquisition of Aetna in November 2018. The new firm could end up playing a bigger role in a health care environment that seems likely to feature more virtual medical checkups and hyper-localized care. CVS’ purchase also helps expand its reach as Amazon (AMZN - Free Report) and others venture into the pharmaceutical business.
Any post-earnings momentum from CVS will come as welcome news to investors because we can see that the stock has dramatically underperformed the market over the last three years. CVS stock has also lagged Walgreens Boots Alliance (WBA - Free Report) but topped Rite Aid .
Outlook
Our current Zacks Consensus Estimate calls for CVS’ Q4 revenues to reach $53.71 billion. This would represent an 11% jump from the prior-year quarter and easily beat Q3’s 2.4% top-line expansion and Q4 2017’s 5.3% growth. Meanwhile, CVS’ same-store retail sales are projected to jump 4.69% and pharmacy comps are expected to pop 6.41%, based on our NFM estimates. Investors should note that both of these would mark a downturn from the third quarter.
Moving on, CVS is projected to see its adjusted quarterly earnings pop 7.81% to hit $2.07 per share. This would also mark a downturn from Q3’s 15.3% bottom-line expansion. Plus, CVS has seen its earnings estimate revision picture turn negative over the last 60 days for Q4 and coming periods.
CVS is scheduled to release its Q4 2018 financial results before the market opens on Wednesday. So make sure to come back to Zacks for a full break down of CVS’ actual metrics after fellow giant Walmart (WMT - Free Report) reported stronger-than-expected fourth quarter financial results Tuesday.
Is Your Investment Advisor Fumbling Your Financial Future?See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”Click to get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
CVS Health (CVS - Free Report) shares jumped 0.50% during regular trading hours Tuesday in continuation of a strong month for the pharmacy firm. So, let’s see what to expect from CVS’ fourth-quarter financial results that are due out before the opening bell Wednesday.
Overview
CVS completed its nearly $70 billion acquisition of Aetna in November 2018. The new firm could end up playing a bigger role in a health care environment that seems likely to feature more virtual medical checkups and hyper-localized care. CVS’ purchase also helps expand its reach as Amazon (AMZN - Free Report) and others venture into the pharmaceutical business.
Any post-earnings momentum from CVS will come as welcome news to investors because we can see that the stock has dramatically underperformed the market over the last three years. CVS stock has also lagged Walgreens Boots Alliance (WBA - Free Report) but topped Rite Aid .
Outlook
Our current Zacks Consensus Estimate calls for CVS’ Q4 revenues to reach $53.71 billion. This would represent an 11% jump from the prior-year quarter and easily beat Q3’s 2.4% top-line expansion and Q4 2017’s 5.3% growth. Meanwhile, CVS’ same-store retail sales are projected to jump 4.69% and pharmacy comps are expected to pop 6.41%, based on our NFM estimates. Investors should note that both of these would mark a downturn from the third quarter.
Moving on, CVS is projected to see its adjusted quarterly earnings pop 7.81% to hit $2.07 per share. This would also mark a downturn from Q3’s 15.3% bottom-line expansion. Plus, CVS has seen its earnings estimate revision picture turn negative over the last 60 days for Q4 and coming periods.
CVS is scheduled to release its Q4 2018 financial results before the market opens on Wednesday. So make sure to come back to Zacks for a full break down of CVS’ actual metrics after fellow giant Walmart (WMT - Free Report) reported stronger-than-expected fourth quarter financial results Tuesday.
Is Your Investment Advisor Fumbling Your Financial Future?See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”Click to get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AMZN - FREE
Get the latest research report on WMT - FREE
Get the latest research report on CVS - FREE
Get the latest research report on WBA - FREE